{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:25:09Z","timestamp":1787005509658,"version":"build-2736575974"},"reference-count":57,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Folate-based small molecule drug conjugates (SMDCs) are currently under development and have shown promising preclinical and clinical results against various cancers and polycystic kidney disease. Two requisites for response to a folate-based SMDC are (i) folate receptor alpha (FR\u03b1) protein is expressed in the diseased tissues, and (ii) FR\u03b1 in those tissues is accessible and functionally competent to bind systemically administered SMDCs. Here we report on the development of a small molecule reporter conjugate (SMRC), called EC2220, which is composed of a folate ligand for FR\u03b1 binding, a multilysine containing linker that can cross-link to FR\u03b1 in the presence of formaldehyde fixation, and a small hapten (fluorescein) used for immunohistochemical detection. Data show that EC2220 produces a far greater IHC signal in FR\u03b1-positive tissues over that produced with EC17, a folate-fluorescein SMRC that is released from the formaldehyde-denatured FR\u03b1 protein. Furthermore, the extent of the EC2220 IHC signal was proportional to the level of FR\u03b1 expression. This EC2220-based assay was qualified both in vitro and in vivo using normal tissue, cancer tissue, and polycystic kidneys. Overall, EC2220 is a sensitive and effective reagent for evaluating functional and accessible receptor expression in vitro and in vivo.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.9b00624","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T17:11:46Z","timestamp":1564420306000},"page":"3985-3995","source":"Crossref","is-referenced-by-count":6,"title":["Detecting Functional and Accessible Folate Receptor\nExpression in Cancer and Polycystic Kidneys"],"prefix":"10.1021","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-3379","authenticated-orcid":true,"given":"Haiyan","family":"Chu","sequence":"first","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Shillingford","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Westrick","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Nelson","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia Z.","family":"Wang","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Parker","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert E.","family":"Felten","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy F.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Cun","family":"Xu","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjuan J.","family":"Lu","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iontcho R.","family":"Vlahov","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Leamon","sequence":"additional","affiliation":[{"name":"Endocyte, Inc. , 3000 Kent Avenue, Suite A1-100 , , ,","place":["West Lafayette, Indiana, United\nStates, 47906"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"issue":"8","key":"2026081717211328600_cit1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3557","article-title":"Serine,\nglycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Locasale","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"2026081717211328600_cit2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality\nand gene regulation of\nfolate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv. Drug Delivery Rev."},{"issue":"10","key":"2026081717211328600_cit3","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin\nslows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"2026081717211328600_cit4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor\nexpression in carcinomas and normal\ntissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"issue":"9","key":"2026081717211328600_cit5","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/1097-0142(19940501)73:9&lt;2432::AID-CNCR2820730929&gt;3.0.CO;2-S","article-title":"Differential regulation of folate\nreceptor isoforms in normal and malignant tissues in vivo and in established\ncell lines. Physiologic and clinical implications","volume":"73","author":"Ross","year":"1994","journal-title":"Cancer"},{"issue":"12","key":"2026081717211328600_cit6","first-page":"3396","article-title":"Distribution of\nthe folate receptor GP38 in normal and malignant cell lines and tissues","volume":"52","author":"Weitman","year":"1992","journal-title":"Cancer Res."},{"issue":"2","key":"2026081717211328600_cit7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2&lt;193::AID-IJC10&gt;3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian\ncancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int. J. Cancer"},{"key":"2026081717211328600_cit8","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.2147\/DDDT.S90670","article-title":"A current review of folate receptor\nalpha as a potential tumor target in non-small-cell lung cancer","volume":"9","author":"Shi","year":"2015","journal-title":"Drug Des., Dev. Ther."},{"issue":"6A","key":"2026081717211328600_cit9","first-page":"3567","article-title":"Alpha-folate\nreceptor expression in epithelial ovarian carcinoma and non-neoplastic\novarian tissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res."},{"issue":"5","key":"2026081717211328600_cit10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ijc.22811","article-title":"Folate\nreceptor overexpression is associated with poor outcome in breast\ncancer","volume":"121","author":"Hartmann","year":"2007","journal-title":"Int. J. Cancer"},{"key":"2026081717211328600_cit11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2193-1801-1-22","article-title":"Folate\nreceptor alpha (FRA) expression in breast cancer: identification of\na new molecular subtype and association with triple negative disease","volume":"1","author":"O\u2019Shannessy","year":"2012","journal-title":"SpringerPlus"},{"issue":"19","key":"2026081717211328600_cit12","first-page":"5329","article-title":"Folate-binding\nprotein is a marker for ovarian cancer","volume":"51","author":"Campbell","year":"1991","journal-title":"Cancer\nRes."},{"issue":"2","key":"2026081717211328600_cit13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19980417)79:2&lt;121::AID-IJC4&gt;3.0.CO;2-V","article-title":"Expression of folate binding protein\nas a prognostic factor for response to platinum-containing chemotherapy\nand survival in human ovarian cancer","volume":"79","author":"Toffoli","year":"1998","journal-title":"Int. J.\nCancer"},{"issue":"2","key":"2026081717211328600_cit14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review\nof mirvetuximab soravtansine in the treatment of platinum-resistant\novarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"issue":"10","key":"2026081717211328600_cit15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and Activity of Mirvetuximab\nSoravtansine (IMGN853),\na Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant\nOvarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion\nStudy","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"2026081717211328600_cit16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/annonc\/mdu024","article-title":"Phase II study of\ntreatment of advanced\novarian cancer with folate-receptor-targeted therapeutic (vintafolide)\nand companion SPECT-based imaging agent (99mTc-etarfolatide)","volume":"25","author":"Morris","year":"2014","journal-title":"Ann. Oncol"},{"issue":"35","key":"2026081717211328600_cit17","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide\n(EC145) and pegylated liposomal doxorubicin (PLD) in combination versus\nPLD alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"2026081717211328600_cit18","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1097\/JTO.0b013e318267d051","article-title":"Multicenter trial\nof EC145 in advanced, folate-receptor\npositive adenocarcinoma of the lung","volume":"7","author":"Edelman","year":"2012","journal-title":"J. Thorac.\nOncol."},{"issue":"8","key":"2026081717211328600_cit19","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.addr.2004.01.004","article-title":"Folate-receptor-targeted\nradionuclide\nimaging agents","volume":"56","author":"Ke","year":"2004","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026081717211328600_cit20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/1097-0215(20010401)92:1&lt;106::AID-IJC1145&gt;3.3.CO;2-Z","article-title":"Influence of the route of administration on targeting\nof ovarian cancer with the chimeric monoclonal antibody MOv18: i.v.\nvs. i.p","volume":"92","author":"van\nZanten-Przybysz","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"5","key":"2026081717211328600_cit21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2967\/jnumed.113.133074","article-title":"Imaging the folate\nreceptor on cancer cells with 99mTc-etarfolatide:\nproperties, clinical use, and future potential of folate receptor\nimaging","volume":"55","author":"Maurer","year":"2014","journal-title":"J. Nucl. Med."},{"key":"2026081717211328600_cit22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/PGPM.S58374","article-title":"Targeted treatment\nof folate receptor-positive platinum-resistant ovarian cancer and\ncompanion diagnostics, with specific focus on vintafolide and etarfolatide","volume":"7","author":"Serpe","year":"2014","journal-title":"Pharmacogenomics Pers. Med."},{"issue":"9","key":"2026081717211328600_cit23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12149-015-1006-2","article-title":"Phase I clinical trial\nof 99mTc-etarfolatide, an imaging agent for folate receptor in healthy\nJapanese adults","volume":"29","author":"Yamada","year":"2015","journal-title":"Ann. Nucl. Med."},{"issue":"8","key":"2026081717211328600_cit24","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1074\/jbc.M310752200","article-title":"Identification of formaldehyde-induced\nmodifications in proteins: reactions with model peptides","volume":"279","author":"Metz","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2026081717211328600_cit25","unstructured":"Xu, L. C., Vlahov, I. R., Leamon, C. P., Santhapuram, H. K.; Li, C.\nH.\n          Synthesis, Purification,\nand Uses of Pteroic Acid and Derivatives and Conjugates Thereof. U.S. Patent No. 8,044,200 B2, October 25, 2011."},{"issue":"2","key":"2026081717211328600_cit26","doi-asserted-by":"publisher","first-page":"R56","DOI":"10.1186\/ar3304","article-title":"Treatment\nof experimental adjuvant arthritis with a novel folate receptor-targeted\nfolic acid-aminopterin conjugate","volume":"13","author":"Lu","year":"2011","journal-title":"Arthritis\nRes. Ther"},{"issue":"4","key":"2026081717211328600_cit27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/CJI.0b013e3182917f59","article-title":"A phase\nI study of folate immune therapy (EC90 vaccine administered with GPI-0100\nadjuvant followed by EC17) in patients with renal cell carcinoma","volume":"36","author":"Amato","year":"2013","journal-title":"J. Immunother."},{"issue":"13","key":"2026081717211328600_cit28","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1158\/0008-5472.CAN-06-3894","article-title":"Folate receptor-specific\nantitumor activity of EC131,\na folate-maytansinoid conjugate","volume":"67","author":"Reddy","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"2026081717211328600_cit29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ng.2715","article-title":"Loss of cilia\nsuppresses cyst growth in genetic models of autosomal dominant polycystic\nkidney disease","volume":"45","author":"Ma","year":"2013","journal-title":"Nat. Genet."},{"issue":"1","key":"2026081717211328600_cit30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone\ndeacetylase 6 activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int."},{"issue":"9","key":"2026081717211328600_cit31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nm.1865","article-title":"An efficient\nand versatile system for acute and chronic modulation of renal tubular\nfunction in transgenic mice","volume":"14","author":"Traykova-Brauch","year":"2008","journal-title":"Nat. Med."},{"issue":"2","key":"2026081717211328600_cit32","doi-asserted-by":"publisher","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison\nof folate-conjugated rapamycin\nversus unconjugated rapamycin in an orthologous mouse model of polycystic\nkidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am. J. Physiol Renal Physiol"},{"issue":"8","key":"2026081717211328600_cit33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/dvg.20226","article-title":"Nestin-Cre\ntransgenic mouse line Nes-Cre1 mediates highly efficient Cre\/loxP\nmediated recombination in the nervous system, kidney, and somite-derived\ntissues","volume":"44","author":"Dubois","year":"2006","journal-title":"Genesis"},{"issue":"2","key":"2026081717211328600_cit34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1148\/radiol.10090050","article-title":"Breast\ncancers: MR imaging of folate-receptor expression with the folate-specific\nnanoparticle P1133","volume":"255","author":"Meier","year":"2010","journal-title":"Radiology"},{"issue":"5","key":"2026081717211328600_cit35","first-page":"857","article-title":"Preclinical\nevaluation of (99m)\u00adTc-EC20 for imaging folate receptor-positive tumors","volume":"45","author":"Reddy","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026081717211328600_cit36","doi-asserted-by":"publisher","first-page":"F70","DOI":"10.1152\/ajprenal.1997.272.1.F70","article-title":"Internalization and apical-to-basolateral\ntransport of folate in rat kidney proximal tubule","volume":"272","author":"Birn","year":"1997","journal-title":"Am. J. Physiol."},{"issue":"1","key":"2026081717211328600_cit37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/ki.1992.7","article-title":"A high-affinity folate\nbinding protein in proximal tubule cells of human kidney","volume":"41","author":"Holm","year":"1992","journal-title":"Kidney Int."},{"issue":"32","key":"2026081717211328600_cit38","doi-asserted-by":"publisher","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2026081717211328600_cit39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.110.175109","article-title":"Reducing\nundesirable hepatic clearance of a tumor-targeted vinca alkaloid via\nnovel saccharopeptidic modifications","volume":"336","author":"Leamon","year":"2011","journal-title":"J. Pharmacol.\nExp. Ther."},{"issue":"6","key":"2026081717211328600_cit40","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00280-017-3311-z","article-title":"Enhancing the therapeutic range of a targeted small-molecule tubulysin\nconjugate for folate receptor-based cancer therapy","volume":"79","author":"Leamon","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"2026081717211328600_cit41","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1021\/bc060145g","article-title":"Synthesis and biological\nevaluation of EC140: a novel\nfolate-targeted vinca alkaloid conjugate","volume":"17","author":"Leamon","year":"2006","journal-title":"Bioconjugate\nChem."},{"issue":"5","key":"2026081717211328600_cit42","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/mp070049c","article-title":"Preclinical antitumor activity of a novel folate-targeted dual drug\nconjugate","volume":"4","author":"Leamon","year":"2007","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"2026081717211328600_cit43","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-018-27320-5","article-title":"Pre-clinical evaluation\nof EC1456,\na folate-tubulysin anti-cancer therapeutic","volume":"8","author":"Reddy","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"2026081717211328600_cit44","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-07-0033","article-title":"Preclinical evaluation of EC145, a folate-vinca alkaloid\nconjugate","volume":"67","author":"Reddy","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"2026081717211328600_cit45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-005-0151-z","article-title":"Folate receptor\nspecific anti-tumor activity of folate-mitomycin\nconjugates","volume":"58","author":"Reddy","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"2026081717211328600_cit46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0091270009339740","article-title":"Clinical pharmacokinetics\nand exposure-toxicity relationship of a folate-Vinca alkaloid conjugate\nEC145 in cancer patients","volume":"49","author":"Li","year":"2009","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"2026081717211328600_cit47","first-page":"700","article-title":"Evaluation of 111In-DTPA-folate as\na receptor-targeted diagnostic agent for ovarian cancer: initial clinical\nresults","volume":"44","author":"Siegel","year":"2003","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026081717211328600_cit48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1517\/14728222.2015.1083979","article-title":"Therapeutic\ntargets for polycystic kidney disease","volume":"20","author":"Wilson","year":"2016","journal-title":"Expert\nOpin. Ther. Targets"},{"issue":"4","key":"2026081717211328600_cit49","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1046\/j.1523-1755.2003.00232.x","article-title":"Combination treatment\nof PKD utilizing\ndual inhibition of EGF-receptor activity and ligand bioavailability","volume":"64","author":"Sweeney","year":"2003","journal-title":"Kidney Int."},{"issue":"5","key":"2026081717211328600_cit50","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1046\/j.1523-1755.2003.00256.x","article-title":"EGF receptor tyrosine\nkinase inhibition attenuates the development of PKD in Han:SPRD rats","volume":"64","author":"Torres","year":"2003","journal-title":"Kidney Int."},{"issue":"4","key":"2026081717211328600_cit51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards\ncyst growth and\npreserves kidney function in a rodent model for polycystic kidney\ndisease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Pressure Res."},{"issue":"8","key":"2026081717211328600_cit52","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1093\/ndt\/gfp129","article-title":"Long-term\nrapamycin therapy in the Han:SPRD rat model of polycystic kidney disease\n(PKD)","volume":"24","author":"Zafar","year":"2009","journal-title":"Nephrol., Dial., Transplant."},{"issue":"8","key":"2026081717211328600_cit53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus\nattenuates disease progression in an orthologous mouse model of human\nautosomal dominant polycystic kidney disease","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int."},{"issue":"22","key":"2026081717211328600_cit54","doi-asserted-by":"publisher","first-page":"32144","DOI":"10.18632\/oncotarget.8282","article-title":"Intraoperative imaging of folate receptor alpha positive\novarian and breast cancer using the tumor specific agent EC17","volume":"7","author":"Tummers","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"2026081717211328600_cit55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative\ntumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha\ntargeting: first in-human results","volume":"17","author":"van\nDam","year":"2011","journal-title":"Nat. Med."},{"key":"2026081717211328600_cit56","doi-asserted-by":"publisher","first-page":"469047","DOI":"10.1155\/2015\/469047","article-title":"Comparison of Folate Receptor Targeted Optical Contrast\nAgents for Intraoperative Molecular Imaging","volume":"2015","author":"De\nJesus","year":"2015","journal-title":"Int. J. Mol. Imaging"},{"key":"2026081717211328600_cit57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2018.11.019","article-title":"Folate-dactolisib\nconjugates for targeting tubular cells in polycystic kidneys","volume":"293","author":"Shi","year":"2019","journal-title":"J. Controlled Release"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.9b00624","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/9\/3985\/13585911\/mp9b00624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/16\/9\/3985\/13585911\/mp9b00624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:39:57Z","timestamp":1787002797000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/16\/9\/3985\/507384\/Detecting-Functional-and-Accessible-Folate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":57,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,29]]},"published-print":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00624","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]}}}